Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report

BACKGROUND: Immune checkpoint blockade targeting programmed cell death ligand-1 (PD-L1)/programmed death-1 (PD-1) signaling was approved recently for locally advanced and metastatic urothelial bladder carcinoma (UBC). Some patients experience a very rapid tumor progression, rather than clinical bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Shiyu, Zhang, Junfeng, Guo, Yadong, Zhang, Ziwei, Wu, Yuan, Zhang, Wentao, Wang, Longsheng, Geng, Jiang, Yan, Yang, Yao, Xudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333318/
https://www.ncbi.nlm.nih.gov/pubmed/30666091
http://dx.doi.org/10.2147/DDDT.S181122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333318/
https://www.ncbi.nlm.nih.gov/pubmed/30666091
http://dx.doi.org/10.2147/DDDT.S181122

Ejemplares similares